Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure
申请人:Taylor George Malcolm
公开号:US20080090827A1
公开(公告)日:2008-04-17
This invention provides compounds that possess inhibitory activity against β-adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3). This invention further provides pharmaceutical compositions comprising such compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against β-adrenergic receptors and PDE.
COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
申请人:Artesian Therapeutics, Inc.
公开号:EP1830852A2
公开(公告)日:2007-09-12
[EN] COMPOUNDS WITH MIXED PDE-INHIBITORY AND ß-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE<br/>[FR] COMPOSES A ACTIVITE A LA FOIS INHIBITRICE DE LA PDE ET ANTAGONISTE OU AGONISTE PARTIELLE DES RECEPTEURS $G(B)-ADRENERGIQUES POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE
申请人:ARTESIAN THERAPEUTICS INC
公开号:WO2006060127A2
公开(公告)日:2006-06-08
[EN] This invention provides compounds that possess inhibitory activity against ß-adrenergic receptors and phosphodiesterases, including phosphodiesterase 3 (PDE3). This invention further provides pharmaceutical compositions comprising such compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against ß-adrenergic receptors and PDE. [FR] Cette invention concerne des composés qui présentent une activité inhibitrice contre des récepteurs ß-adrénergiques et des phosphodiestérases, y compris la phosphodiestérase 3 (PDE3). Cette invention concerne également des compositions pharmaceutiques renfermant ces composés, des procédés utilisant ces composés pour traiter une maladie cardiovasculaire, un accident vasculaire cérébral, l'épilepsie, un trouble ophtalmique ou la migraine, ainsi que des procédés de préparation de compositions pharmaceutiques et de composés qui présentent une activité inhibitrice contre des récepteurs ß-adrénergiques et la PDE.